Safran : Technically solid
Entry price | Target | Stop-loss | Potential |
---|
€106.9 |
€116 |
€102 |
+8.51% |
---|
The current trading zone is interesting to the point that investors should pay attention to the stock and anticipate a return of the underlying upward trend.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths● The company's profit outlook over the next few years is a strong asset.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses● The firm trades with high earnings multiples: 31.62 times its 2022 earnings per share.
● In relation to the value of its tangible assets, the company's valuation appears relatively high.
● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
● The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.